Mirtazapine Grindeks

Mirtazapine, the active ingredient in Mirtazapine Grindeks, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to improve mood and functional outcomes.

GNH USA supplies Mirtazapine Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory‑compliant documentation for importers.

Mirtazapine is a NaSSA antidepressant used primarily in the management of depressive disorders.

- Major depressive disorder: alleviates depressive symptoms and improves overall mood. - Treatment‑resistant depression: used as an alternative when first‑line agents are ineffective. - Depression with insomnia: provides sedative effects that can improve sleep quality in affected patients.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior, especially early in treatment - Severe hypotension - Hepatic dysfunction - Seizures (rare)

Before initiating therapy, clinicians should consider several safety aspects.

- Hepatic function: assess liver enzymes and adjust if impairment is present. - Suicidality: monitor for worsening depression or emergent suicidal ideation. - Cardiovascular disease: use caution in patients with existing heart conditions. - Elderly patients: start at low dose due to heightened risk of sedation and falls. - Discontinuation: avoid abrupt cessation to reduce risk of withdrawal symptoms. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression. - Benzodiazepines or other CNS depressants: enhanced sedative effect. - Antihistamines: may increase sedation. - Warfarin: monitor INR for possible anticoagulant effect changes. - Anticholinergic drugs: may exacerbate dry mouth and constipation.